Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 5/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
| ▸ | MDM4 | O15151 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29480470 | 0.90 | CTSK (0.57) | PTPN1 | |
| SCHEMBL17446658 | 0.89 | MDM4 (0.46) | PTPN1MDM4TP53CASP3FDFT1 | |
| SCHEMBL17446714 | 0.88 | HDAC1 (0.53) | HDAC1HDAC2TNFMDM4TP53 | |
| SCHEMBL23811018 | 0.88 | KMT2A (0.52) | HDAC1HDAC2TNFMDM4TP53 | |
| SCHEMBL17446655 | 0.87 | HDAC1 (0.50) | PTPN1HDAC1HDAC2 | |
| SCHEMBL29480487 | 0.87 | CTSK (0.51) | PTPN1HDAC1HDAC2TNFMDM4 | |
| SCHEMBL17446656 | 0.84 | PTPN1 (0.46) | PTPN1HDAC1HDAC2TNFMDM4 | |
| SCHEMBL29715771 | 0.84 | PTPN1 (0.46) | PTPN1HDAC1HDAC2TNFMDM4 | |
| SCHEMBL17446719 | 0.84 | PTPN1 (0.48) | PTPN1HDAC1HDAC2TNFMDM4 | |
| SCHEMBL19177183 | 0.84 | PTPN1 (0.43) | PTPN1HDAC1HDAC2TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170210778-A1 | NOVEL COMPOUNDS | INVIVOGEN SAS (FR) | 2017-07-27 | — | — | US | disclosed |
| WO-2016008946-A1 | NOVEL COMPOUNDS | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2016-01-21 | — | — | WO | disclosed |
| EP-2975046-A1 | Novel compounds | The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth (IE) | 2016-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210778-A1 | NOVEL COMPOUNDS | F12, C1R, F11 | PTPN1 2412/4885HDAC1 747/4885HDAC2 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.